research Budesonide for maintenance of remission in Crohn's disease
Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.
Search
for
Sort by
Research
840-870 / 1000+ results
research Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
research Estudio comparativo de dos complementos alimenticios inhibidores de la 5a-reductasa en la alopecia androgénica femenina
The higher dose supplement was more effective in treating female hair loss.
research Melatonin preparations in dermatological practice
Melatonin can improve treatment and extend remission for certain skin conditions.
research PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort
The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children
Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
research Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
research 5 alpha-reductase inhibition by a new synthetic steroid (PM-9) in cultures of Penicillium crustosum.
PM-9, like finasteride, may help treat certain diseases by blocking a key enzyme.
research The Clinical Efficacy and Mechanism of Action of Alitretinoin in the Treatment of Alopecia Areata
Alitretinoin may help treat mild to moderate alopecia areata.
research Winding the clock back on female androgenetic alopecia
Reversing female hair loss.
research Characteristics and Outcomes of Patients on Tofacitinib for Alopecia Areata or Rheumatoid Arthritis: A Retrospective Cohort Study
Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
research 93 Approach to Managing Recalcitrant Alopecia Areata With Combination Therapy: A Series of Five Cases in Black Pediatric Patients
Combination therapy, including JAK inhibitors, effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.
research 76221 Faster Onset and Superior Efficacy of an Investigational Extended-Release Oral Minoxidil Tablet (VDPHL01) Versus Topical and Immediate-Release Oral Minoxidil for Androgenetic Alopecia: Results from a Blinded Retrospective Investigator Global Assessment
research 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
research Topische Immuntherapie mit Diphenylcyclopropenon bei verschiedenen Typen der Alpecia areata: Assoziation zu klinischen Parametern und einem funktionellen Genpolymorphismus des Interleukin-6-Promotors
Topical immunotherapy with DPCP is most effective for certain alopecia areata types, with success linked to age and disease duration, and influenced by a gene polymorphism.
research Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study
Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.
research Tacrolimus in Dermatologic Disorders
Topical tacrolimus is safe and effective for skin conditions, but oral tacrolimus has serious side effects.
research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research Ivarmacitinib in atopic dermatitis presenting with prurigo nodularis-like lesions and alopecia areata: a case report
Ivarmacitinib may effectively treat complex atopic dermatitis and related hair loss.
research P4 Outcome following switch between brand name and generic tacrolimus in paediatric population
Switching to generic tacrolimus was safe, effective, and saved money.
research Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
research Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
research Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
Baricitinib significantly regrows hair in teens with severe alopecia areata.
research Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
research Betamethasone valerate/minoxidil/tretinoin
The combination of tretinoin, minoxidil, and betamethasone valerate may cause severe scalp inflammation.
research Modified platelet rich plasma therapy for alopecia totalis
The combined treatment helps improve severe hair loss and reduces the need for other medications.
research Treatment of moderate-to-severe alopecia areata in patients over the age of 65 with baricitinib
Baricitinib helps treat severe hair loss in people over 65.
research Urticaria pigmentosa-like skin disease in a domestic shorthair cat
A cat with severe skin issues improved with dexamethasone and cetirizine.